|
1
|
Vézina C, Kudelski A and Sehgal SN:
Rapamycin (AY-22,989), a new antifungal antibiotic. I Taxonomy of
the producing streptomycete and isolation of the active principle.
J Antibiot. 28:721–726. 1975. View Article : Google Scholar
|
|
2
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Benjamin D, Colombi M, Moroni C and Hall
MN: Rapamycin passes the torch: A new generation of mTOR
inhibitors. Nat Rev Drug Discov. 10:868–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim DH, Sarbassov DD, Ali SM, King JE,
Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: mTOR
interacts with raptor to form a nutrient-sensitive complex that
signals to the cell growth machinery. Cell. 110:163–175. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoeffer CA and Klann E: mTOR signaling: At
the crossroads of plasticity, memory and disease. Trends Neurosci.
33:67–75. 2010. View Article : Google Scholar
|
|
8
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar
|
|
9
|
Guertin DA and Sabatini DM: An expanding
role for mTOR in cancer. Trends Mol Med. 11:353–361. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu K, Liu P and Wei W: mTOR signaling in
tumorigenesis. Biochim Biophys Acta. 1846:638–654. 2014.PubMed/NCBI
|
|
11
|
Beauchamp EM and Platanias LC: The
evolution of the TOR pathway and its role in cancer. Oncogene.
32:3923–3932. 2013. View Article : Google Scholar
|
|
12
|
Fasolo A and Sessa C: Targeting mTOR
pathways in human malignancies. Curr Pharm Des. 18:2766–2777. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar
|
|
14
|
Bielack S and Carrle D: Osteosarcoma: ESMO
clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 20(Suppl 4): S137–S139. 2009. View Article : Google Scholar
|
|
15
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
16
|
Ottaviani G and Jaffe N: The etiology of
osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar
|
|
17
|
Anderson PM and Pearson M: Novel
therapeutic approaches in pediatric and young adult sarcomas. Curr
Oncol Rep. 8:310–315. 2006. View Article : Google Scholar
|
|
18
|
Mori M, Hitora T, Nakamura O, Yamagami Y,
Horie R, Nishimura H and Yamamoto T: Hsp90 inhibitor induces
autophagy and apoptosis in osteosarcoma cells. Int J Oncol.
46:47–54. 2015.
|
|
19
|
Egas-Bejar D, Anderson PM, Agarwal R,
Corrales-Medina F, Devarajan E, Huh WW, Brown RE and Subbiah V:
Theranostic profiling for actionable aberrations in advanced high
risk osteosarcoma with aggressive biology reveals high molecular
diversity: The human fingerprint hypothesis. Oncoscience.
1:167–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pignochino Y, Dell'Aglio C, Basiricò M,
Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D,
Torchiaro E, et al: The combination of sorafenib and everolimus
abrogates mTORC1 and mTORC2 upregulation in osteosarcoma
preclinical models. Clin Cancer Res. 19:2117–2131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Betz C and Hall MN: Where is mTOR and what
is it doing there? J Cell Biol. 203:563–574. 2013. View Article : Google Scholar :
|
|
22
|
Ashworth RE and Wu J: Mammalian target of
rapamycin inhibition in hepatocellular carcinoma. World J Hepatol.
6:776–782. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hara K, Maruki Y, Long X, Yoshino K,
Oshiro N, Hidayat S, Tokunaga C, Avruch J and Yonezawa K: Raptor, a
binding partner of target of rapamycin (TOR), mediates TOR action.
Cell. 110:177–189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Harris TE, Roth RA and Lawrence JC
Jr: PRAS40 regulates mTORC1 kinase activity by functioning as a
direct inhibitor of substrate binding. J Biol Chem.
282:20036–20044. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guertin DA, Stevens DM, Thoreen CC, Burds
AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ and Sabatini DM:
Ablation in mice of the mTORC components raptor, rictor, or mLST8
reveals that mTORC2 is required for signaling to Akt-FOXO and
PKCalpha, but not S6K1. Dev Cell. 11:859–871. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peterson TR, Laplante M, Thoreen CC,
Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM: DEPTOR is an
mTOR inhibitor frequently overexpressed in multiple myeloma cells
and required for their survival. Cell. 137:873–886. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Laplante M and Sabatini DM: mTOR signaling
at a glance. J Cell Sci. 122:3589–3594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang Y, Vilella-Bach M, Bachmann R,
Flanigan A and Chen J: Phosphatidic acid-mediated mitogenic
activation of mTOR signaling. Science. 294:1942–1945. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sengupta S, Peterson TR and Sabatini DM:
Regulation of the mTOR complex 1 pathway by nutrients, growth
factors, and stress. Mol Cell. 40:310–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Finn RS: Current and future treatment
strategies for patients with advanced hepatocellular carcinoma:
Role of mTOR inhibition. Liver Cancer. 1:247–256. 2012. View Article : Google Scholar
|
|
32
|
Pyo JO, Nah J and Jung YK: Molecules and
their functions in autophagy. Exp Mol Med. 44:73–80. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bayascas JR and Alessi DR: Regulation of
Akt/PKB Ser473 phosphorylation. Mol Cell. 18:143–145. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:E5564–E5573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kuijjer ML, van den Akker BE, Hilhorst R,
Mommersteeg M, Buddingh EP, Serra M, Bürger H, Hogendoorn PC and
Cleton-Jansen AM: Kinome and mRNA expression profiling of
high-grade osteosarcoma cell lines implies Akt signaling as
possible target for therapy. BMC Med Genomics. 7:42014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Freeman SS, Allen SW, Ganti R, Wu J, Ma J,
Su X, Neale G, Dome JS, Daw NC and Khoury JD: Copy number gains in
EGFR and copy number losses in PTEN are common events in
osteosarcoma tumors. Cancer. 113:1453–1461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou Q, Deng Z, Zhu Y, Long H, Zhang S and
Zhao J: mTOR/p70S6K signal transduction pathway contributes to
osteosarcoma progression and patients' prognosis. Med Oncol.
27:1239–1245. 2010. View Article : Google Scholar
|
|
39
|
Di Cristofano C, Leopizzi M, Miraglia A,
Sardella B, Moretti V, Ferrara A, Petrozza V and Della Rocca C:
Phosphorylated ezrin is located in the nucleus of the osteosarcoma
cell. Mod Pathol. 23:1012–1020. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wan X, Mendoza A, Khanna C and Helman LJ:
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine
model of osteosarcoma. Cancer Res. 65:2406–2411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tanaka M, Yamazaki T, Araki N, Yoshikawa
H, Yoshida T, Sakakura T and Uchida A: Clinical significance of
tenascin-C expression in osteosarcoma: Tenascin-C promotes distant
metastases of osteosarcoma. Int J Mol Med. 5:505–510.
2000.PubMed/NCBI
|
|
42
|
Zheng L, Zhang D, Zhang Y, Wen Y and Wang
Y: mTOR signal transduction pathways contribute to TN-C FNIII A1
overexpression by mechanical stress in osteosarcoma cells. Mol
Cells. 37:118–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao S, Lu N, Chai Y and Yu X: Rapamycin
inhibits tumor growth of human osteosarcomas. J BUON. 20:588–594.
2015.PubMed/NCBI
|
|
44
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Goudarzi KM, Nistér M and Lindström MS:
mTOR inhibitors blunt the p53 response to nucleolar stress by
regulating RPL11 and MDM2 levels. Cancer Biol Ther. 15:1499–1514.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song R, Tian K, Wang W and Wang L: P53
suppresses cell proliferation, metastasis, and angiogenesis of
osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway. Int J
Surg. 20:80–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang X, Lai P, Zhang Z, Huang M, Wang L,
Yin M, Jin D, Zhou R and Bai X: Targeted inhibition of mTORC2
prevents osteosarcoma cell migration and promotes apoptosis. Oncol
Rep. 32:382–388. 2014.PubMed/NCBI
|
|
48
|
Fleuren ED, Versleijen-Jonkers YM, Roeffen
MH, Franssen GM, Flucke UE, Houghton PJ, Oyen WJ, Boerman OC and
van der Graaf WT: Temsirolimus combined with cisplatin or
bevacizumab is active in osteosarcoma models. Int J Cancer.
135:2770–2782. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wagner LM, Fouladi M, Ahmed A, Krailo MD,
Weigel B, DuBois SG, Doyle LA, Chen H and Blaney SM: Phase II study
of cixutumumab in combination with temsirolimus in pediatric
patients and young adults with recurrent or refractory sarcoma: A
report from the Children's Oncology Group. Pediatr Blood Cancer.
62:440–444. 2015. View Article : Google Scholar
|
|
50
|
Xie ZG, Xie Y and Dong QR: Inhibition of
the mammalian target of rapamycin leads to autophagy activation and
cell death of MG63 osteosarcoma cells. Oncol Lett. 6:1465–1469.
2013.PubMed/NCBI
|
|
51
|
Horie R, Nakamura O, Yamagami Y, Mori M,
Nishimura H, Fukuoka N and Yamamoto T: Apoptosis and antitumor
effects induced by the combination of an mTOR inhibitor and an
autophagy inhibitor in human osteosarcoma MG63 cells. Int J Oncol.
48:37–44. 2016.
|
|
52
|
Gupte A, Baker EK, Wan SS, Stewart E, Loh
A, Shelat AA, Gould CM, Chalk AM, Taylor S, Lackovic K, et al:
Systematic Screening identifies dual PI3K and mTOR inhibition as a
conserved therapeutic vulnerability in osteosarcoma. Clin Cancer
Res. 21:3216–3229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhu YR, Min H, Fang JF, Zhou F, Deng XW
and Zhang YQ: Activity of the novel dual phosphatidylinositol
3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against
osteosarcoma. Cancer Biol Ther. 16:602–609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gobin B, Battaglia S, Lanel R, Chesneau J,
Amiaud J, Rédini F, Ory B and Heymann D: NVP-BEZ235, a dual
PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and
tumor development in vivo with an improved survival rate. Cancer
Lett. 344:291–298. 2014. View Article : Google Scholar
|
|
55
|
Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH,
He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, et al: Pro-apoptotic and
pro-autophagic effects of the Aurora kinase A inhibitor alisertib
(MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the
activation of mitochondria-mediated pathway and inhibition of p38
MAPK/PI3K/Akt/mTOR signaling pathway. Drug Des Devel Ther.
9:1555–1584. 2015.PubMed/NCBI
|
|
56
|
Slotkin EK, Patwardhan PP, Vasudeva SD, de
Stanchina E, Tap WD and Schwartz GK: MLN0128, an ATP-competitive
mTOR kinase inhibitor with potent in vitro and in vivo antitumor
activity, as potential therapy for bone and soft-tissue sarcoma.
Mol Cancer Ther. 14:395–406. 2015. View Article : Google Scholar
|
|
57
|
Grignani G, Palmerini E, Ferraresi V,
D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al Italian Sarcoma Group: Sorafenib and
everolimus for patients with unresectable high-grade osteosarcoma
progressing after standard treatment: A non-randomised phase 2
clinical trial. Lancet Oncol. 16:98–107. 2015. View Article : Google Scholar
|
|
58
|
Chawla SP, Staddon AP, Baker LH, Schuetze
SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L,
et al: Phase II study of the mammalian target of rapamycin
inhibitor ridaforolimus in patients with advanced bone and soft
tissue sarcomas. J Clin Oncol. 30:78–84. 2012. View Article : Google Scholar
|
|
59
|
Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G
and Gao Q: Lupeol induces apoptosis and cell cycle arrest of human
osteosarcoma cells through PI3K/AKT/mTOR pathway. Technol Cancer
Res Treat. Oct 6–2015.(Epub ahead of print). pii:
1533034615609014.
|
|
60
|
Liu WN, Lin JH, Cheng YR, Zhang L, Huang
J, Wu ZY, Wang FS, Xu SG, Lin WP, Lan WB, et al: FIM-A, a
phosphorus-containing sirolimus, inhibits the angiogenesis and
proliferation of osteosarcomas. Oncol Res. 20:319–326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhou R, Zhang Z, Zhao L, Jia C, Xu S, Mai
Q, Lu M, Huang M, Wang L, Wang X, et al: Inhibition of mTOR
signaling by oleanolic acid contributes to its anti-tumor activity
in osteosarcoma cells. J Orthop Res. 29:846–852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li G, Cai M, Fu D, Chen K, Sun M, Cai Z
and Cheng B: Heat shock protein 90B1 plays an oncogenic role and is
a target of microRNA-223 in human osteosarcoma. Cell Physiol
Biochem. 30:1481–1490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lin S, Shao NN, Fan L, Ma XC, Pu FF and
Shao ZW: Effect of microRNA-101 on proliferation and apoptosis of
human osteosarcoma cells by targeting mTOR. J Huazhong Univ Sci
Technolog Med Sci. 34:889–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yao C, Wei JJ, Wang ZY, Ding HM, Li D, Yan
SC, Yang YJ and Gu ZP: Perifosine induces cell apoptosis in human
osteosarcoma cells: New implication for osteosarcoma therapy? Cell
Biochem Biophys. 65:217–227. 2013. View Article : Google Scholar
|
|
65
|
Moriceau G, Ory B, Mitrofan L, Riganti C,
Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG,
et al: Zoledronic acid potentiates mTOR inhibition and abolishes
the resistance of osteosarcoma cells to RAD001 (Everolimus):
Pivotal role of the prenylation process. Cancer Res.
70:10329–10339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jiang H and Zeng Z: Dual mTORC1/2
inhibition by INK-128 results in antitumor activity in preclinical
models of osteosarcoma. Biochem Biophys Res Commun. 468:255–261.
2015. View Article : Google Scholar : PubMed/NCBI
|
